Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $124,952.

  • ProQR Therapeutics N.V's Cash & Equivalents rose 27.27% to $124,952 in Q3 2025 from the same period last year, while for Sep 2025 it was $124,952, marking a year-over-year increase of 27.27%. This contributed to the annual value of $159.7 million for FY2024, which is 24.11% up from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics N.V's Cash & Equivalents is $124,952, which was down 99.93% from $169.1 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Revenue - Interest and Investment Income high stood at $69,571 for Q3 2022, and its period low was -$90,353 during Q3 2023.
  • Its 3-year average for Cash & Equivalents is $93.0 million, with a median of $128.1 million in 2024.
  • Data for ProQR Therapeutics N.V's Revenue - Interest and Investment Income shows a maximum YoY plummeted of 229.87% (in 2023) over the last 5 years.
  • Over the past 5 years, ProQR Therapeutics N.V's Cash & Equivalents (Quarterly) stood at $214.5 million in 2021, then crashed by 54.93% to $96.7 million in 2022, then skyrocketed by 32.33% to $128.0 million in 2023, then slumped by 99.88% to $159,657 in 2024, then grew by 27.27% to $124,952 in 2025.
  • Its Cash & Equivalents stands at $124,952 for Q3 2025, versus $169.1 million for Q2 2025 and $157.2 million for Q1 2025.